@article {1052,
	title = {Radiohalogens for imaging and therapy},
	journal = {Chemical Society Reviews},
	volume = {34},
	number = {2},
	year = {2005},
	note = {ISI Document Delivery No.: 890PETimes Cited: 34Cited Reference Count: 41},
	pages = {153-163},
	type = {Review},
	abstract = {Radiohalogens play a very important role in radiopharmaceuticals used for medical imaging ( now referred to as molecular imaging) and therapy applications. Development of new radiopharmaceuticals that have radiohalogens incorporated requires an understanding of parameters that are unique to chemistry involving these radionuclides. Those parameters include requirement for production and purification of the halogen radionuclides, as well as development of reaction conditions for use with high specific activity short-lived radionuclides. In this tutorial review, several radiohalogens, their radiolabeling chemistry and their application to medical imaging and therapy are discussed.},
	keywords = {BRAIN, CANCER, F-18, LIGAND, MONOCLONAL-ANTIBODIES, PET, POSITRON-EMISSION-TOMOGRAPHY, RADIOIODINATION, RADIOTHERAPY, SPECT},
	isbn = {0306-0012},
	url = {<Go to ISI>://000226522500005},
	author = {Adam,Michael J. and Wilbur, D. S.}
}
@article {4306,
	title = {Indirect enzyme-linked immunosorbent assay for the quantitative estimation of lysergic acid diethylamide in urine},
	journal = {Clinical Chemistry},
	volume = {44},
	number = {5},
	year = {1998},
	note = {ISI Document Delivery No.: ZL795Times Cited: 5Cited Reference Count: 27},
	month = {May},
	pages = {985-990},
	type = {Article},
	abstract = {A new antibody to lysergic acid diethylamide (LSD) was used to develop a novel indirect ELISA for the quantification of drug in urine. Evaluation of the new assay with the commercially available LSD ELISA (STC Diagnostics) shows improved performance. The test requires 50 mu L of urine, which is used to measure concentrations of drug in the mu g/L to ng/L range. The Limit of detection was 8 ng/L compared with 85 ng/L in the commercial assay, and analytical recoveries were 98-106\%. Our test detected 0.1 mu g/L of LSD in urine with an intraassay CV of 2.4\% (n = 8) compared with 6.0\% for a 0.5 mu g/L sample in the commercial assay (n = 20). The upper and lower limits of quantification were estimated to be 7 mu g/L and 50 ng/L, respectively. Specificity was evaluated by measuring the extent of cross-reactivity with 24 related substances. Drug determination using the new assay offers both improved sensitivity and precision compared with existing methods, thus facilitating the preliminary quantitative estimation of LSD in urine at lower concentrations with a greater degree of certainty.},
	keywords = {AFFINITY, BODY-FLUIDS, ELISA, GAS-CHROMATOGRAPHY, METABOLITES, MONOCLONAL-ANTIBODIES, N-DEMETHYL-LSD, RADIOIMMUNOASSAY, SERUM, TANDEM MASS-SPECTROMETRY},
	isbn = {0009-9147},
	url = {<Go to ISI>://000073472300014},
	author = {Kerrigan, S. and Brooks, D. E.}
}
